September 22, 2011
Canonsburg, Pa.-based Mylan Inc. said Tuesday it has received tentative US approval for a generic version of an HIV treatment regimen. Included in the regimen are generic versions of GlaxoSmithKline PLC's Epivir (lamivudine), Gilead Sciences Inc.'s Viread (tenofovir), and Boehringer Ingelheim's Viramune (nevirapine). Mylan said its subsidiary, Matrix Laboratories Ltd., received clearance from the Food and Drug Administration through the President's Emergency Plan for AIDS Relief. Eligible for sale outside the United States, the regimen will be offered in some developing nations.